Q2 EPS Forecast for Aquestive Therapeutics Cut by Analyst

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.22) for the quarter, down from their previous forecast of ($0.15). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Aquestive Therapeutics' Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.82) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.75) EPS.

Several other analysts have also commented on AQST. Lake Street Capital dropped their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Finally, Raymond James set a $7.00 price objective on Aquestive Therapeutics in a report on Friday, March 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Aquestive Therapeutics has an average rating of "Buy" and an average price target of $10.67.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $2.38 on Monday. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $5.80. The stock's 50 day moving average is $2.76 and its two-hundred day moving average is $3.34. The firm has a market cap of $236.40 million, a P/E ratio of -5.29 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million during the quarter, compared to analysts' expectations of $12.23 million.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors have recently made changes to their positions in AQST. Pale Fire Capital SE boosted its stake in shares of Aquestive Therapeutics by 154.1% in the first quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company's stock worth $3,873,000 after acquiring an additional 809,928 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock worth $2,457,000 after acquiring an additional 621,614 shares during the last quarter. Stifel Financial Corp boosted its stake in shares of Aquestive Therapeutics by 315.4% in the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company's stock worth $1,419,000 after acquiring an additional 302,617 shares during the last quarter. Harvey Capital Management Inc. boosted its stake in shares of Aquestive Therapeutics by 1,419.3% in the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock worth $952,000 after acquiring an additional 249,790 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Aquestive Therapeutics in the first quarter worth approximately $686,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.